In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page

New GVP Product- or Population-Specific Considerations IV published by EMA

by In2Pharma | Dec 19, 2018 | News

EMA EMA published the new good pharmacovigilance practice (GVP) Product- or Population-Specific Considerations IV containing specific considerations about pharmacovigilance for the pediatric population. It explains the importance of pediatric pharmacovigilance, the...

Recent Posts

  • Planned legislative updates NL
  • Update RD 06.09.2017 pregabalin/gabapentin
  • Update New Inspection Platform GDP – FAMHP
  • Luxembourg tightens rules on nicotine pouches and novel nicotine products from 2026  
  • Specific claims in NL for food supplements

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België